• Ligand Pharmaceuticals Inc., of San Diego, signed a license agreement with Curx Pharmaceuticals Inc., also of San Diego, to develop and commercialize Ligand's Captisol-enabled Topiramate Injection for partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate. Ligand will be eligible for more than $21 million in potential net milestone payments and net royalties on future sales of 6 percent to 7.5 percent.